Gut Microbes (Dec 2023)

Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies

  • Mijra Koning,
  • Hilde Herrema,
  • Max Nieuwdorp,
  • Abraham S. Meijnikman

DOI
https://doi.org/10.1080/19490976.2023.2226922
Journal volume & issue
Vol. 15, no. 1

Abstract

Read online

ABSTRACTHumans possess abundant amounts of microorganisms, including bacteria, fungi, viruses, and archaea, in their gut. Patients with nonalcoholic fatty liver disease (NAFLD) exhibit alterations in their gut microbiome and an impaired gut barrier function. Preclinical studies emphasize the significance of the gut microbiome in the pathogenesis of NAFLD. In this overview, we explore how adjusting the gut microbiome could serve as an innovative therapeutic strategy for NAFLD. We provide a summary of current information on untargeted techniques such as probiotics and fecal microbiota transplantation, as well as targeted microbiome-focused therapies including engineered bacteria, prebiotics, postbiotics, and phages for the treatment of NAFLD.

Keywords